



REVIEW ARTICLE

Biological Evidences of Dicoumarol: A Review

Khaled Rashed

Department of Pharmacognosy, National Research Centre, 33 El Bohouth st.-Dokki, Giza, P.O.12622, EGYPT

*Corresponding Author: khalednabih2015@yahoo.co.uk

Manuscript Details

Manuscript Submitted : 16/01/2021
Manuscript Revised : 10/03/2021
Manuscript Accepted : 14/03/2021
Manuscript Published : 22/03/2021

Available On

<https://plantaescientia.com/ojs>

Cite This Article As

Khaled R., (2021). Biological evidences of dicoumarol: A review. *Pla. Sci.* 2021; Vol. 04 Iss. 02:121-124.

Copyright



© The Author(s). 2020. Open Access
This article is distributed under the terms
of the Creative Commons Attribution
4.0 International License

<http://creativecommons.org/licenses/by/4.0/>

Indexed In

[CrossRef](#), [Scientific Indexing Services \(SIS\)](#), [Google Scholar](#), [Index Copernicus International \(ICI\)](#), [Directory of Research Journal Indexing \(DRJI\)](#), [CiteFactor](#), [Scientific Journal Impact Factor \(SJIF\)](#), [General Impact Factor](#), [Journal Factor](#), [Cosmos Impact Factor](#), [PKP Index](#), [AJIFACTOR Indexing](#), etc.

ABSTRACT

Dicoumarol, a natural anticoagulant drug chemically designated as is metabolized from Coumarin in the sweet clover (*Melilotus alba* and *Melilotus officinalis*) by molds, such as *Penicillium nigricans* and *Penicillium jensi*. Coumarin (1,2-benzopyrone), the parent molecule of Dicoumarol, is the simplest compound of a large class of naturally occurring phenolic substances made of fused Benzene and Pyrone rings. In addition, the Coumarin anticoagulants, Dicoumarol (Dicoumarol) and its synthetic derivative Warfarin sodium (Coumadin), have been shown to decrease metastases in experimental animals. Warfarin sodium, largely replacing Dicoumarol therapeutically as an anticoagulant, has been used for the treatment of a variety of cancers and shown to improve tumor response rates and survival in patients with several types of cancer. However, despite numerous studies, little information has been acquired on the cellular mechanism of action of Coumarin compounds in the treatment of malignancies. Possibly for this reason, the Coumarin compounds have not received much attention for the treatment of cancer.

Keywords: Dicoumarol, Chemical compounds, Plants, Bioactivities

INTRODUCTION

Phytochemicals are chemical compounds that occur naturally in the plant kingdom. Some are responsible for the organoleptic properties of the natural sources in which they are present. The term is generally used to refer to those chemicals that may have biological significance, for example carotenoids, flavonoids, coumarins, or chromones, but not all are established as essential nutrients. There may be as many as 4,000 different phytochemicals having potential activity against several diseases such as cancer and metabolic or degenerative diseases. Coumarins have been isolated from hundreds of plants species distributed in more than 40 different families. There were isolated more than different 1300 coumarins, well distributed in Angiospermae, Monocotyledoneae and Dicotyledoneae families. Coumarinic compounds are a class of lactones structurally constructed by a benzene ring fused to α -pyrone ring, and essentially possess-conjugated system with rich electron and good charge-transport properties (Murray *et.al.*, 1982 & Murray RDH 1997).

Dicoumarol, a symmetrical biscoumarin can be considered as the “parent” of the widely used anticoagulant drug, warfarin. The discovery of dicoumarol’s bioactive properties resulted from an investigation into a mysterious cattle disease in the 1940s. Dicoumarol (3,3'-methylenebis(4-hydroxy-2H-chromen-2-one). It was subsequently identified as a fungal metabolite of coumarin and the main cause of sweet clover disease, a haemorrhagic disease of cows and other livestock (Campbell & Link, 1941; Gomez-Outes *et. al.* 2012). Dicoumarol can fatally inhibit clotting in farm animals, it was used pharmacologically as an anticoagulant (Greisman & Marcus, 1948). It also had some use as a rat poison in agriculture (Armour & Barnett, 1950). However, in both applications it was superseded by the related compound warfarin (Keeling *et al*, 2011; Tadros & Shakib, 2010).

Warfarin has the advantage of being more potent than dicoumarol and the sodium salt can be administered orally or by injection (Link, 1959) Dicoumarol continued to be used in the laboratory for a variety of applications, including as an uncoupler of the mitochondrial or bacterial membrane proton motive force (Van & Slater ,2015-2019). In recent years, it has once again been receiving attention as a potential lead molecule in drug discovery—this time for anti-cancer agents, rather than for anticoagulants. This review gave the major bioactivities of dicoumarol compound.

BIOLOGICAL ACTIVITIES

Anticoagulant effect

Coagulation refers to the physiological process that blood flows from a flowing liquid state to a non-flowing gel state. The essence of coagulation is the process that soluble fibrinogen in plasma changes into insoluble fibrin. Vitamin K is necessary for the liver synthesis of coagulation factors and thus antagonists of vitamin K can be used as anticoagulants in clinical practice (Norm *et al*, 2014). Dicoumarol has a similar core structure with vitamin K. Hence it can competitively antagonize with vitamin K and inhibit the synthesis Of coagulation factors in the liver. Further studies showed that vitamin K epoxide reductase complex subunit 1 (VKORC1), a vitamin K cyclase, is the target of dicoumarol (Wallin *et al*, 2008).

Anticancer effect

Dicoumarol exerts an inhibitory effect on cell viability, cell proliferation, and induces apoptosis in a variety of cancers such as cholangiocarcinoma, osteosarcoma, mastadenoma, leucocythemia, renal carcinoma, and melanoma. Dicoumarol ligand with sodium adduct exerts cytotoxicity in U2OS human bone osteosarcoma epithelial cells (Rehman *et al*, 2013). Dicoumarol arrests the cell cycle in G0/1 phase by increasing the cellular superoxide in HL-60 human myeloid leukemia cells (Bello *et al*, 2005). It induces apoptosis of cancer cells in a concentration- and time-dependent manner, which was mediated by oxidative stress, cytochrome c release followed by activation of caspase-9 and cleavage of caspase-3 (Cullen *et al* 2003). Furthermore, it induces apoptosis in MCF-7 breast cancer cells but shows no toxicity on oocyte maturation and ovarian tissues of the mouse (Aras *et al*, 2015).

Antimicrobial and antiviral activities

Dicoumarol and a series of its derivatives containing Cu²⁺ complexes exerted the antibacterial activity including gram-positive bacterium *Bacillus subtilis* ATCC11774 and *Streptococcus pyogenes* ATCC12384), m-negative bacterium (*Pseudomonas aeruginosa* ATCC25619 and *herichia coli* ATCC25922) and *Mycobacterium tuberculosis* H37Ra. It also exerts antifungal activity like *Aspergillus niger* ATCC64958 and *Candida albicans* ATCC66027 (Dholaria *et al*, 2013; Tian *et al*, 2013). 2-Pyridinodicoumarol (2-PyDC), dicoumarol derivative, exerts antibacterial activity in four *Staphylococcus aureus* bacterial strains, including *S. aureus* ATCC 29213, MRSA 75302, Mu50 and USA 300 LAC with the minimal inhibitory concentration (MIC) ranging from 16 to 64 $\mu\text{g}/\text{mL}$ (Hou *et al*, 2014). Dicoumarol inhibits coli nitroreductase enzyme, an activating enzyme for nitroaromatic drugs of the dinitrobenzamide class (Johanson *et al*, 2003).

Neurotoxicity

The neurotoxicity of dicoumarol may result from its inhibition of NQO1, which plays a protective role in the dopaminergic system of the substantia nigra striatum (Diaz-Veliz et al, 2004). Thus, as an inhibitor of NQO1, dicoumarol may increase the damage to the nigrostriatal dopaminergic system when used in combination with other medicines. For instance, a combination of aminochrome and dicoumarol for 48h induced. Approximately 70 % cell death in the RCSN-3 neuronal dopaminergic cell line (Munoz et al, 2012).

Hepatotoxicity and lymphotoxicity

Liver-specific side effects are rare in dicoumarol treatment, but there are reports of inflammatory infiltration, hepatocyte necrosis, and liver failure. Therefore, transaminase and cholestasis parameters should be checked regularly. If there is unclear liver disease, the medication treatment should be weaned off immediately (Castedal, 1998). Dicoumarol enhanced the production of menadione induced strand breaks in isolated human lymphocytes (Woods et al, 1997). In the absence of serum, dicoumarol showed significant cytotoxicity to HL-60 cells (Forthoffer et al, 2002).

CONCLUSION

This review showed the importance of dicoumarol as a medicinal compound. The discovery of dicoumarol as an anticoagulant is an example, which opens the development of coumarins anticoagulant drugs as warfarin, acenocoumarol, ethyl biscoumacetate, etc. The main mechanism of this category of drug is by interfering with the metabolism of vitamin K. Beside its anticoagulant effect, dicoumarol and its derivatives show anticancer, antimicrobial, antiviral activities. Furthermore, other targets for dicoumarol such as NQO1 have been identified, which might provide potential applications other than an anticoagulant. However, the side reactions, especially hemorrhagic complications, need to be avoided in clinical practice though it has been used for several decades.

REFERENCES

Aras D., O. Cinar, Z. Cakar, S. Ozkavukcu, A. Can, (2015). Can dicoumarol be used as a gonad-safe anticancer agent: an in vitro and in vivo experimental study, *Mol. Hum. Reprod.* 22 (1) 57–67. <https://doi.org/10.1093/molehr/gav065>

Armour CJ, Barnett SA. (1950). The action of dicoumarol on laboratory and wild rats, and its effect on feeding behaviour. *Epidemiology & Infection* 48: 158-170. <https://doi.org/10.1017/s0022172400014984>

Bello R.I., C. Gomez-Diaz, G. Lopez-Lluch, N. Forthoffer, M.C. Cordoba-Pedregosa, P. Navas, J.M. Villalba, (2005). Dicoumarol relieves serum withdrawal-induced G0/1 blockade in HL-60 cells through

a superoxide-dependent mechanism, *Biochem. Pharmacol.* 69 (11) 1613–1625. <https://doi.org/10.1016/j.bcp.2005.03.012>

Campbell HA, Link KP. (1941). Studies on the hemorrhagic sweet clover disease: IV. The isolation and crystallization of the hemorrhagic agent. *Journal of Biological Chemistry* PP 138: 21-33. [https://doi.org/10.1016/s0021-9258\(18\)51407-1](https://doi.org/10.1016/s0021-9258(18)51407-1)

Castedal M., F. Aldenborg, R. Olsson, (1998). Fulminant hepatic failure associated with dicoumarol therapy, *Liver* 18 (1) 67–69. <https://doi.org/10.1111/j.1600-0676.1998.tb00129.x>

Cullen JJ., M.M. Hinkhouse, M. Grady, A.W. Gaut, J. Liu, Y.P. Zhang, C.J. Darby Weydert, F.E. Domann, L.W. Oberley, (2003). Dicoumarol inhibition of NADPH:quinone oxidoreductase induces growth inhibition of pancreatic cancer via a superoxide-mediated mechanism, *Cancer Res.* 63 (17) 5513. [https://doi.org/10.1016/s0016-5085\(03\)81462-2](https://doi.org/10.1016/s0016-5085(03)81462-2)

Dholariya H.R., K.S. Patel, J.C. Patel, K.D. Patel, (2013). Dicoumarol complexes of Cu(II) based on 1,10-phenanthroline: synthesis, X-ray diffraction studies, thermal behavior and biological evaluation, *Spectrochim. Acta A Mol. Biomol. Spectrosc.* 108 319–328. <https://doi.org/10.1016/j.saa.2012.09.096>

Diaz-Veliz G., S. Mora, H. Lungenstrass, J. Segura-Aguilar, (2004). Inhibition of DT- diaphorase potentiates the in vivo neurotoxic effect of intranigral injection of salsolinol in rats, *Neurotox. Res.* 5 (8) 629–633. <https://doi.org/10.1007/bf03033183>

Du J., D.H. Daniels, C. Asbury, S. Venkataraman, J. Liu, D.R. Spitz, L.W. Oberley, J. J. Cullen, (2006). Mitochondrial production of reactive oxygen species mediate dicoumarol-induced cytotoxicity in cancer cells, *J. Biol. Chem.* 281 (49) 37416–37426. <https://doi.org/10.1074/jbc.m605063200>

Forthoffer N., C. Gomez-Diaz, R.I. Bello, M.I. Buron, S.F. Martin, J.C. Rodriguez- Aguilera, P. Navas, J.M. Villalba, (2002). A novel plasma membrane quinone reductase and NAD(P)H:quinone oxidoreductase I are upregulated by serum withdrawal in human promyelocytic HL-60 cells, *J. Bioenerg. Biomembr.* 34 (3) 209–219. <https://doi.org/10.1023/a:1016035504049>

Gomez-Outes A, Suarez-Gea ML, Calvo-Rojas G, Lecumberri R, Rocha E, Pozo-Hernandez C, Terleira-Fernandez AI, Vargas-Castrillon E. (2012). Discovery of anticoagulant drugs: a historical perspective. *Curr Drug Discov Technol* 9: 83-104. <https://doi.org/10.2174/1570163811209020083>

Greisman H, Marcus RM.(1948). Acute myocardial infarction; detailed study of dicoumarol therapy in 75 consecutive cases. *Am Heart J*36: 600-609. [https://doi.org/10.1016/0002-8703\(48\)90694-2](https://doi.org/10.1016/0002-8703(48)90694-2)

Hou J. Li, Z., G.H. Chen, F. Li, Y. Zhou, X.Y. Xue, Z.P. Li, M. Jia, Z.D. Zhang, M. K. Li, X.X. Luo, (2014). Synthesis, antibacterial activities, and theoretical studies of dicoumarols, *Org. Biomol. Chem.* 12 (29) 5528–5535. <https://doi.org/10.1039/c4ob00772g>

Johansson E., G.N. Parkinson, W.A. Denny, S. Neidle, (2003). Studies on the nitroreductase prodrug-activating system. Crystal structures of complexes with the inhibitor dicoumarol and dinitrobenzamide prodrugs and of the enzyme active form, *J. Med. Chem.* 46 (19) 4009–4020. <https://doi.org/10.2210/pdb1oo5/pdb>

Keeling D, Baglin T, Tait C, Watson H, Perry D, Baglin C, Kitchen S, Makris M, (2011). British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin - fourth edition. *Br J Haematol*; 154: 311-324. <https://doi.org/10.1111/j.1365-2141.2011.08753.x>

Lewis A., M. Ough, L. Li, M.M. Hinkhouse, J.M. Ritchie, D.R. Spitz, J.J. Cullen, (2004). Treatment of pancreatic cancer cells with dicoumarol induces cytotoxicity and oxidative stress, *Clin. Cancer Res.* 10 (13) 4550. <https://doi.org/10.1158/1078-0432.ccr-03-0667>

Link KP. (1959). The Discovery of Dicoumarol and Its Sequels. *Circulation* 19: 97-107 <https://doi.org/10.1161/01.cir.19.1.97>

Munoz P., S. Huenchuguala, I. Paris, C. Cuevas, M. Villa, P. Caviedes, J. Segura- Aguilar, Y. Tizabi, (2012). Protective effects of nicotine against aminochrome-induced toxicity in substantia nigra derived cells: implications for Parkinson's disease, *Neurotox. Res.* 22 (2) 177-180. <https://doi.org/10.1007/s12640-012-9326-7>

Murray RDH, Mendez J, Brown SA.(1982). The natural coumarins occurrence. In *Chemistry and Biochemistry*. Chichester, UK: John Wiley and Sons.

Murray RDH. (1997). Naturally occurring plant coumarins. *Progress in the Chemistry of Or-ganic Natural Products.*72:1-119.

Norn S., H. Permin, E. Kruse, P.R. Kruse, (2014). On the history of vitamin K, dicoumarol and warfarin, *Dan. Medicinhist. Arbog* 42:99-119.

Rehman S., M. Ikram, A. Khan, S. Min, E. Azad, T.S. Hofer, K. Mok, R.J. Baker, A. J. Blake, S.U. Rehman, (2013). New dicoumarol sodium compound: crystal structure, theoretical study and tumoricidal activity against osteoblast cancer cells, *Chem. Cent. J.* 7 (1) 110. <https://doi.org/10.1186/1752-153x-7-110>

Tadros R, Shakib S. (2010). Warfarin--indications, risks and drug interactions. *Aust Fam Physician* 39: 476-479.

Tian Z., Q. Yan, L. Feng, S. Deng, C. Wang, J. Cui, C. Wang, Z. Zhang, T.D. James, X. Ma, (2019). A far-red fluorescent probe for sensing laccase in fungi and its application in developing an effective biocatalyst for the biosynthesis of antituberculous dicoumarin, *Chem. Commun. (Camb.)* 55 (27) 3951-3954. <https://doi.org/10.1039/c9cc01579e>

Van Dam K, Slater EC. (2015-2019). A suggested mechanism of uncoupling of respiratory-chain phosphorylation. *Proc Natl Acad Sci U S A* 1967; 58. <https://doi.org/10.1073/pnas.58.5.2015>

Wallin R., N. Wajih, S.M. Hutson, (2008) VKORC1: a warfarin-sensitive enzyme in vitamin K metabolism and biosynthesis of vitamin K-dependent blood coagulation factors, *Vitam. Horm.* 78; 227-246. [https://doi.org/10.1016/s0083-6729\(07\)00011-8](https://doi.org/10.1016/s0083-6729(07)00011-8)

Woods J.A., A.J. Young, I.T. Gilmore, A. Morris, R.F. Bilton, (1997). Measurement of menadione-mediated DNA damage in human lymphocytes using the comet assay, *Free Radic. Res.* 26 (2) 113-124. <https://doi.org/10.3109/10715769709097790>

Plantae Scientia, 2021